Clinical trials: Multicentric Castleman s Disease
Idiopathic Multicentric Castleman's Disease
A Study of Anti-IL-6R mAb Injection in Patients With iMCD
This study is a single-arm, open-label, multicenter, dose-escalation clinical study. Its primary purpose is to evaluate the safety and tolerability of recombinant humanized anti-interleukin-6 receptor monoclonal antibody …
- Trial name
- NCT05345522
- Testing
- Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w, Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w
- Where
- 3 sites in China
- Volunteers
- 25 people
- Sponsor
- Beijing VDJBio Co., LTD.